It is now over a decade since the first nuclear receptor coactivator, SRC-1, was cloned and discovered to be a new type of transcription factor that does not bind DNA, but rather, binds directly or indirectly to nuclear receptors (NRs) to mediate their transcriptional potency. The NR coactivators belong to a class of molecules now termed 'coregulators'. Employing an 'operational' definition, we define coactivators as molecules which enhance transcription, and corepressors as molecules which repress transcription. Current evidence indicates that this operational definition can be modified by gene, cell and signaling context for any one coregulator. Our current understanding is that NRs and other DNA-binding transcription factors (TFs) search out the target genes to be regulated by binding to specific DNA sequences (or other TFs at such sequences) termed TF-response elements (1); the second job of NRs is to recruit the coregulators that perform all of the subsequent reactions needed to induce or repress expression of genes. Initially, we believed that coactivators were simply 'adapters' that stabilized the general transcription machinery at the TATA box. This explanation proved to be incorrect. Over the past decade, the mechanistic importance of coregulators has expanded logarithmically, and we now realize that they perform virtually 'all' of the reactions needed for control of enhancer dependent gene expression.
tremendous and puzzling heterogeneity of the molecules. We could not understand why they appeared so numerous and difficult to characterize via charge and size separation columns. In 1989, the Towle lab published similar results that TR associated with heat-denaturable proteins in crude nuclear extracts of tissues in a manner altered by ligand (7) . It was not until over two decades later that we realized and confirmed that these 'acceptor sites' that we were investigating were actually part of the hundreds of NR coactivators now known to be present in nuclear chromatin.
Almost always in biology, progress occurs as the result of cumulative data produced by many labs which then eventually evolve into a final molecular concept. It is my opinion that the Ptashne lab provided some of the first guiding principles, demonstrating in yeast cells that protein-protein interactions between transcription factors can directly control inhibition or activation of genes; they showed that GAL80, an inhibitor of the yeast transcriptional activator GAL4, can be converted into an activator by insertion of an acidic activating sequence (8) . This hybrid activator did not bind to DNA directly, but was brought to DNA by interacting with a derivative of GAL4 that bound to both the GAL80 and DNA. Ptashne's work rekindled the interest of a number of labs working on TF-associated proteins in animal cells.
A series of papers beginning in the 1990's, presented excellent examples of Drosophila proteins that bind to TBP, termed TAFs, are part of the TFIID complex that interacts with the promoter (TATA box) via TBP (9) . The Tjian lab showed that they regulated basal promoter activity, and he termed them 'coactivators' in some of his publications. However, they are not coactivators as we now know them in the NR field. They help TBP during basal transcription to recruit Pol II to the promoter start-site for transcription (and even receive some signals from upstream kinases, etc.), but they were not the long-sought 'enhancer' regulatory proteins that mediate signal-dependent regulation of genes in mammals. The TAFs, however, have no common sequence homology with the 270+ classical mammalian coactivators isolated subsequently, and that regulate genes via upstream enhancer elements.
In another study, B cell-restricted activity required for high levels of octamer/Oct-dependent transcription from an immunoglobulin heavy chain (IgH) promoter was detected in an in vitro system by the Roeder lab (10) . The factor responsible for this activity was designated Oct coactivator from B cells (OCA-B) and was shown to stimulate transcription from an IgH promoter in conjunction with either Oct-1 or Oct-2 but showed no significant effect on the octamer/Oct-dependent transcription of the ubiquitously expressed histone H2B promoter. OCA-B was likely a coactivator-type of protein activity. During this time period, receptor-receptor squelching experiments were published by our lab (11) and by Chambon's lab (12) ; the results of these squelching experiments were as might be predicted from Ptashne's earlier yeast studies, and furthered the idea that undiscovered cellular mediators of NR actions might exist in mammalian cells.
Experiments toward Coregulators
The ability of NRs to repress transcription was studied since the 1980's, mostly with TR, but molecular mechanisms were scarce. In 1992, two papers established some principles for NR regulation by corepressors. In these publications, mutagenesis approaches in yeast and mammalian cells and cell-free proteolytic and epitope mapping analyses established that PR (and RAR) contains a 'repressor domain' in the caboxy-terminal tail of the receptor that silences its transactivation potential (13) ; this silencing was relieved by a conformational change induced by agonist (but not antagonist) in which the tail flips over like the lid of a box (confirmed some years later by X-ray crystallization) (14) . This newly formed surface was later shown to provide a landing platform for coregulators. Next, our lab published proof-of-principle experiments for a cellular corepressor protein using two nuclear receptors (ER and PR). In yeast cells, we showed that a protein, termed SSN6, binds to the TAF1 activation domain of estrogen receptor and suppresses hormone dependent activity (15) . Mutations that prevented this protein-protein interaction increased NR activity by 4-orders of magnitude in the presence of hormone, but not in the presence of anti-hormones. The data suggested that the role of hormone is two-fold: it promotes DNA binding and also induces a conformational change in receptor that overcomes the corepressor function in cells.
Soon after the above publications, Herskowitz and Yamamoto reported that hormone-independent immunoprecipitation of glucocorticoid receptor derivatives from wild-type (SWI+) yeast extracts coprecipitated the SWI3 a protein(s) that binds to RNA polymerase. Receptor-SWI3 complexes were not detected in swi1-or swi2-mutant strains, implying for the first time that a 'complex' of multiple proteins may associate with the receptor (16) . Prior incubation of a Drosophila embryo transcription extract with the yeast SWI3-specific antibody inhibited receptor function in vitro whereas the antibody had no effect if added after formation of the initiation complex. Thus, the glucocorticoid receptor appeared to require an interaction with one or more SWI proteins to function positively in yeast.
In 1994, the Goodman lab identified CBP, an important nuclear protein of M(r) 265K, which bound specifically to the PKA-phosphorylated form of CREB and also interacted with the basal transcription factor TFIIB (17) . Consistent with its role as a coregulator, CBP augmented the activity of phosphorylated CREB to activate transcription of cAMP-responsive genes. Although no studies were carried out with nuclear receptors at this juncture, subsequent studies have revealed that CBP and p300 are general coregulators that, in one way or another, appear to be ubiquitous integrative components in virtually all eukaryotic transcription complexes.
The Brown lab utilized fractionated cell extracts to reveal 160,000 dalton estrogen interacting proteins termed ERAP160. The protein fraction exhibited 'estradiol-dependent binding to the receptor'. Mutational analysis of the estrogen receptor showed that its ability to activate transcription correlated with its ability to bind ERAP160 (18) . Antiestrogens were unable to promote ERAP160 binding. This significant publication suggested that ERAP160 proteins could be mediators of estradiol-dependent transcriptional activation by the estrogen receptor. Although the lab did not purify ERAP160 or clone the molecules, this publication was an important encouragement in the race by multiple labs to identify a specific coactivator molecule.
During this time frame, we were investigating a molecule that we found to function as a coactivator protein by binding and activating the TAF2 of estrogen receptor in yeast and primate cells (19) . This was a yeast protein, termed SPT6, that interacted directly and specifically with the hormone binding domain of hER (TAF2) in vitro and in vivo and was a mediator of hormonal signal transmission. The study was critical to allow us to predict the criteria by which a mammalian coactivator could be identified.
In the same month as our publication of SPT6 coactivator, we published the first biochemical discovery of a soluble cellular 'corepressor' for a nuclear receptor (hTR) and accurately predicted the currently accepted concept for coregulator function: that 'corepressor exchange with a coactivator' is the mechanism for ligand-induced activation of nuclear receptors in primate cells (20) . The existence of corepressors was substantiated definitively by the Evans and Rosenfeld-Glass labs when they separately published the clonings of two specific and important corepressors, SMRT and NCoR (21, 22) A significant advancement towards coactivators was provided by the Moore lab when they used a yeast interaction trap to isolate partial clones encoding peptides that interacted with the ligand binding domain of the rat TR beta (23) . Several related proteins, called Trips (TR-interacting proteins), were isolated from independent selections carried out either in the presence or absence of T3. The Trips were shown to be dependent on hormone (T3) for binding the TR. Although no characterizations were performed, a considerable number of these proteins represented peptide fragments of what were later proven to be authentic NR coregulators.
The Parker lab characterized a novel nuclear protein, RIP140, that specifically interacts in vitro with the AF2 domain of the estrogen receptor (24) . This interaction was increased by estrogen, but not by anti-estrogens and the in vitro binding capacity of mutated estrogen receptors for RIP140 correlated with their ability to stimulate transcription. Since RIP140 interacted with estrogen receptor in intact cells, they originally suggested it might be a coactivator for NRs. The Gustafsson lab, however, later showed RIP140 to be a corepressor. Recently, Parker has shown that the RIP140 corepressor is a protein of major biological importance for adipogenesis and reproduction.
At that time in 1995, an authenticated nuclear receptor interacting coregulator (SRC-1) was finally cloned (25) . From this point forward, 'recruitment of coactivators' was accepted as the mechanism for the gene-inductive function of NRs, thus providing the missing cornerstone in the 'hormone action pathway'. The focus of 'authenticity' is directed to SRC-1 because in one relatively short paper, the following criteria for coactivators were substantiated: (1) coactivators bind to NRs (directly or indirectly), (2) coactivators do not bind to DNA directly; (3) agonist ligands promote coactivator binding to NRs; (4) antagonist ligands inhibit binding of coactivators to receptors; (5) coactivators are able to reverse receptor-receptor squelching; (6) overexpression of coactivators greatly enhances transcriptional capacity, and; (7) coactivator dominant negative molecules knock down endogenous ligand-dependent NR function when introduced into cells.
The Era of Coregulator Physiology. Our lab then went on to prove that coactivators are physiologic regulators in vivo in animals and that even closely related coactivators (i.e., SRC-1 and SRC-3) are non-redundant and have differing specific cellular gene regulatory functions (26, 27) . For the most part, these newly emerging coactivators where shown to be enzymes by multiple lab groups (28, 29, 30, 31) and to function as large molecular complexes of proteins (32, 33) . Interestingly, regulation of the cellular levels of coregulators occurs not via traditional transcriptional mechanisms, but rather, at the level of their degradation (34) . The stage was now set for the plethora of studies pertaining to coregulator biology that were published over the next decade which illustrated their great importance as 'master genes' in all phases of normal physiology and medicine, including cancer, metabolism, cardiovascular, G.I., reproductive, neurological, genetic, and toxicology.
Master Genes Exist The elucidation of coactivator function allowed a new understanding that coactivators were not just adaptors for upstream regulatory sequence communication to TBP as previously thought, (35) but were major regulators and coordinators of many aspects of hormone-receptor physiology, including the concepts of tissue specificity of response, selective receptor modulator function, hormone inductive kinetics, integration of membrane and nuclear signaling, nuclear coordination of mitochondria, mRNA translation, and cell motility processes (33) . In fact, the genes which code for coregulators appear to be the long sought 'Master Genes' of Britten and Davidson (5), designed to coordinately control many diverse DNA-binding transcription factors in order to implement major physiologic processes within the cell such as inflammation, fat and carbohydrate metabolism, and cell growth (36, 5, 3, 4) . For purposes of this mini-review, I define 'Master Genes' as genes coding for coregulator molecules that can coordinately regulate subfunctions of many other TFs, in addition to cell processes such as translation, energy generation, and motility. For example, they are to be distinguished from rate-limiting master TFs of differentiation such as myoD in myocytes.
Important physiological regulators frequently are targets for pathologies and the coregulators are no exception. There have been >270 of the coregulator molecules identified to date. This number would provide an enormous combinatorial potential for multi-task regulation of the great number of genetic processes required in human physiology. Already, ~160 of the coregulators have been associated in publications with some pathologic state (www.NURSA.org). The most frequent of the pathologies are a variety of cancers in which coregulators have been shown to serve as either oncogenes or tumor suppressors, depending upon signaling and cell context. Even with the recent explosion of information on coregulators over the past decade, I have the distinct impression that we are only viewing the tip of the iceberg of what remains to be learned for these fascinating master regulators.
